
    
      Triple negative breast cancer patients with high risk factor will be randomized to receive
      either zoledronic acid or observation after the completion of standard
      chemotherapy/radiotherapy. Recurrence status will be followed and Disease free survival will
      be compared. Overall survival is the secondary endpoint.
    
  